Open AccessCetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis
Author(s) -
Tobias Förster,
Felix J. Huettner,
Christoph Springfeld,
Matthias Loehr,
Eva Kalkum,
Matthes Hackbusch,
Thilo Hackert,
Markus K. Diener,
Pascal Probst
Publication year - 2019
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000502844
Subject(s) - cetuximab , medicine , pancreatic cancer , hazard ratio , oncology , meta analysis , randomized controlled trial , odds ratio , confidence interval , adjuvant therapy , cancer , progression free survival , colorectal cancer , chemotherapy
The present study evaluated the potential benefit of adding cetuximab to neoadjuvant, adjuvant, or palliative standard therapy for pancreatic cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom